### Losartan

**Indication** | Essential hypertension  
--- | ---  
**INN** | Losartan  
**Medicine type** | Chemical agent  
**List type** | Core  
**Formulations** | Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet  
**EML status history** | First added in 2017 (TRS 1006)  
| Changed in 2021 (TRS 1035)  
**Sex** | All  
**Age** | Adolescents and adults  
**Therapeutic alternatives** | Medicines within the same pharmacological class can be used  
**Therapeutic alternatives limitations** | Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup: C09CA Angiotensin II receptor blockers (ARBs), plain.  
**Patent information** | Patents have expired in most jurisdictions  
Read more about patents.  
**Wikipedia** | Losartan  
**DrugBank** | Losartan  

---

**Summary of evidence and Expert Committee recommendations**

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that medicines in 4th level ATC chemical subgroup, C09CA Angiotensin II receptor blockers (ARBs), plain, be specified as therapeutic alternatives under the square box listing for losartan on the EML for this indication.